Medical genetics and genomic medicine in Japan

Area of Science:

• Medical genetics
• Public health policy
• Rare disease research

Background:

• Japan has achieved universal healthcare since 1961, resulting in high life expectancy and low infant mortality.
• The National Program on Rare and Intractable Diseases, established in 1972, supports patients and promotes research.
• Over half of the diseases in the program are Mendelian disorders, driving genetic research.

Purpose of the Study:

• To highlight Japan's advancements in rare and intractable disease management.
• To showcase the impact of national programs on medical genetics research.
• To introduce recent genomic medicine initiatives in Japan.

Main Methods:

• Analysis of Japan's universal healthcare system's health outcomes.
• Review of the National Program on Rare and Intractable Diseases' scope and impact.
• Overview of government-supported genomic medicine initiatives.

Main Results:

• Universal healthcare contributes to excellent public health indicators.
• The National Program has significantly advanced rare disease research, identifying numerous causative genes.
• Government support has spurred genomic medicine initiatives, including undiagnosed disease programs and variant databases.

Conclusions:

• Japan's integrated approach to healthcare and rare disease research has yielded significant public health benefits.
• Continued government investment in genomic medicine promises further advancements in diagnosing and treating rare genetic disorders.
• The success of national programs underscores the importance of policy in driving scientific discovery and patient support.